ESMO 2023 Prostate Cancer - Results from #40

Viewing 41-60 of 66 articles

ESMO 2023: Real-World Analysis of Metastatic Hormone-Sensitive Prostate Cancer: Are Randomized Clinical Trials More Trustworthy? Insights from PIONEER, the European Network of Excellence for Big Data in Prostate Cancer

ESMO 2023: Utilisation Rates of Treatment Intensification for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in England, UK

ESMO 2023: Low- and High- Volume Disease in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): From CHAARTED to PSMA PET

ESMO 2023: Effect of Rapid Ultra-Low Prostate-Specific Antigen Decline (UL PSA) in TITAN Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Who Received Apalutamide plus Androgen Deprivation Therapy

ESMO 2023: Prostate Specific Membrane Antigen Positron Emission Tomography - Directed Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: Implications for the STAMPEDE-2 Trial Design

ESMO 2023: PROSTRATEGY: A SOGUG Randomized Trial of Androgen Deprivation Therapy plus Docetaxel +/- Nivolumab or Ipilimumab-Nivolumab in High-Volume Metastatic Hormone-Sensitive Prostate Cancer - Efficacy Results from the Pilot Phase

ESMO 2023: PC-PEP, a Comprehensive Daily Six-Month Home-Based Prostate Cancer - Patient Empowerment Program Improves Quality of Life, Physical Fitness, and Urinary Function Outcomes Among Prostate Cancer Patients with Localized Disease: Secondary Analyses

ESMO 2023: PSMA Guided Approach for bIoCHEmical Relapse after Prostatectomy-PSICHE Trial

ESMO 2023: The Health Inequality Impact of Darolutamide for Non-Metastatic Castration-Resistant Prostate Cancer – A Distributional Cost-Effectiveness Analysis

ESMO 2023: Prostate Radiotherapy Reduces Long-Term Risk of Obstructive Uropathy in Metastatic Hormone Sensitive Prostate Cancer: Results from the STAMPEDE M1|RT Comparison

ESMO 2023: A Newly-Developed Deep-Learning Algorithm: NAFNet Outperforms ResNet50 for Predicting Adverse Pathology Events and Biochemical Recurrence Time Using MRI from Prostate Cancer Patients

ESMO 2023: Enzalutamide Monotherapy for the Treatment of Prostate Cancer with High-Risk Biochemical Recurrence: EMBARK Secondary Endpoints

ESMO 2023: Treatment of High-Risk Biochemically Recurrent Prostate Cancer with Enzalutamide in Combination with Leuprolide Acetate: Secondary Endpoints from EMBARK

ESMO 2023: ICECaP-2: Validation of Metastasis-Free Survival as a Surrogate for Overall Survival in Localized Prostate Cancer in a More Contemporary Era

ESMO 2023: HRD Complete, a Novel Next Generation Sequencing Assay for Detecting Homologous Recombination Repair Gene Alterations in Prostate Cancer

ESMO 2023: A Novel Machine Learning Based Method to Detect Homozygous Deletion of Homologous Recombination Repair (HRR) Genes in Prostate Cancer

ESMO 2023: First Real-Life Data on 177Lu-PSMA-617: Descriptive Analysis on the Largest Metastatic Castration Resistant Prostate Cancer Cohort Treated in Early Access in France

ESMO 2023: Phase 1/2 Trial of Oral EPI-7386 in Combination with Enzalutamide Compared to Enzalutamide Alone in mCRPC Subjects: Current Phase 1 results

ESMO 2023: Association of Health-Related Quality of Life with Efficacy Outcomes in the VISION Study of Patients with mCRPC

ESMO 2023: ARASTEP: Darolutamide + ADT in Patients with High-Risk BCR Prostate Cancer – A Phase 3 Study

1
2
3
4